SUSMED,Inc.
Notice Regarding Reallocation of Funds Usage
Reason for change: reallocation of funds for R&D in the DTx product business, personnel investments, and office expansion. New disclosure targets include increases in R&D funding, increases in personnel investments, and increased office expansion costs. Expected impact going forward is minor.
Key Figures
- R&D funding: 1,916 million yen
- Human resources investment: 1,240 million yen
- Office space expansion: 288 million yen
AI要約
Rationale and Background
Based on a board resolution, a portion of the funds allocated at listing has been reallocated. Reallocation of funds for clinical development of the DTx product business, recruitment and personnel costs, and office space expansion has been reallocated. Under the previous plan, funds were to be allocated primarily to R&D, with personnel investment and office expansion funded accordingly; however, in line with progress in clinical development and the need to strengthen the organization, the amounts for each item have been revised.
Details of Changes and Future Operating Policy
Within the updated approximate net amount of 3,444 million yen, funds will be allocated to (1) R&D: 1,916 million yen, (2) personnel investment: 1,240 million yen, and (3) office space expansion: 288 million yen. The remaining balance will be allocated as new development pipeline opportunities arise and clinical trial funding needs emerge; until payment timing is decided, funds will be managed in financial instruments with high safety.
SUSMED,Inc.
Company overview · Stock price · Financial data · All IR
